You are here
Novelmed Therapeutics Inc
UEI: D5B7ANZ8LE45
# of Employees: 12
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Disease Modifying Treatment for Hemolytic Disorders
Amount: $533,165.00ABSTRACT Our lead drug candidate is being developed as a disease modifying, potent and efficacious treatment for paroxysmal nocturnal hemoglobinuria (PNH), an “orphan disease”, and is anticipated ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Treatment of Complement-Mediated Myelitis
Amount: $300,000.00ABSTRACT We intend to develop our lead drug candidate as a potent, efficacious, and disease-modifying treatment for the orphan disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), with efficacy an ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Preclinical and Clinical Evaluation of Humanized NM
Amount: $2,436,893.00DESCRIPTION provided by applicant NovelMed has developed an anti properdin antibody hNM for the treatment of intra and extravascular lysis in paroxysmal nocturnal hemoglobinuria PNH The se ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Single Therapy for Wet AMD and Geographic Atrophy
Amount: $548,724.00DESCRIPTION (provided by applicant): Approximately 85% of the total age-related macular degeneration (AMD) patients have the Dry form. Geographic atrophy (GA) is the advanced form of Dry AMD and is ca ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Preclinical and Clinical Evaluation of Humanized NM9405
Amount: $467,832.00ABSTRACT NovelMed has developed an anti-properdin antibody (hNM9405) for the treatment of intra and extravascular lysis in paroxysmal nocturnal hemoglobinuria (PNH). The selection of this antibody was ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Alternative Pathway Inhibitors for Orphan Indication
Amount: $889,438.00DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. I ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis
Amount: $1,451,573.00DESCRIPTION provided by applicant NovelMed intends to develop a humanized anti Bb antibody as a prophylactic treatment for inflammatory responses associated with hemodialysis During this procedur ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
Single Therapy for Wet AMD & Geographic Atrophy
Amount: $588,124.00DESCRIPTION provided by applicant Approximately of the total age related macular degeneration AMD patients have the Dry form Geographic atrophy GA is the advanced form of Dry AMD and is ca ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
Set2Read-AK (Alphabet Knowledge)
Amount: $542,572.00DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. I ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Complement Inhibitors as DMOADs
Amount: $307,870.00DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent amon ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health